Dendrite International Announces Seven Additions to Executive Staff.Business Editors MORRISTOWN, N.J.--(BUSINESS WIRE)--Jan. 21, 2000 Stephen Webb Named Dendrite dendrite: see nervous system; synapse. Senior Vice President of International Group Chris Thomas Chris Thomas may refer to:
Simon was a flash charmer, who had an eye for the ladies. Named Vice Presidents of Dendrite's Global Accounts Gareth D. Thomas Appointed General Manager of Dendrite United Kingdom Bruno Chermette Named Executive Director European Client Service Robert Davis Robert Davis can refer to:
Steve Turner Steve Turner may refer to someone: In professional sports:
for Dendrite Canada Dendrite International, Inc. (Nasdaq/NMS: DRTE DRTE Defence Research Telecommunications Establishment ) announced the addition of seven executives, including three former IMS Health IMS Health (NYSE: RX) is an international consulting and data services company that supplies the pharmaceutical industry with sales data and consulting services. IMS Health was founded in 1954 by Bill Frohlich and David Dubow. Strategic Technologies executives. Stephen Webb has been appointed Senior Vice President of the International Group, Robert Davis has joined as Director of Sales for Canada, and Steve Turner has been named Director of Technical Operations/Client Services for Canada. Four executives will also join Dendrite's United Kingdom headquarters. Dendrite Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. John Bailye made the announcements, saying, &uot;Dendrite is extremely pleased to welcome these individuals to our executive staff. Each brings with him a tremendous knowledge of the pharmaceutical industry that will add greatly to Dendrite's bench strength and to our understanding of clients' present and future needs.&uot; This marks the second announcement in which Walsh/IMS Health ST executives have joined Dendrite as part of the Sales Force Effectiveness provider's strategy and commitment to strengthen and broaden Dendrite's positioning worldwide. In July of this year, Dendrite announced Nigel Whitehead's appointment to Dendrite Vice President of Global Accounts after 15 years with Walsh (part of IMS Health ST). In the newly created role of Dendrite Senior Vice President of the International Group, Stephen Webb, formerly Walsh's Vice President of Europe, will be directly responsible for developing commercial strategies for key accounts in Europe, Japan, Australia/New Zealand, Asia, the Middle East and Africa. &uot;Steve's experience and level of success in this industry is invaluable and unmatched,&uot; said Dendrite Chairman and CEO John Bailye. &uot;The crucial role he played in increasing Walsh's profitability worldwide is remarkable. I am extremely pleased that Steve has chosen to become a member of our executive team at Dendrite.&uot; As Vice President of Europe at Walsh, Webb was responsible for the operations and profitability of twelve countries and a team of approximately 450 employees supplying MIS, Technology and Services specifically focused on major multinational companies. Webb's move to Walsh came after seventeen years at American Cyanamid American Cyanamid was a large, diversified, American chemical manufacturer. Lederle Laboratories, maker of Centrum and Stresstabs vitamins, was Cyanamid's pharmaceutical division. Davis & Geck was the company's medical device division. as General Manager and Director for the Medical Device and Hospital Pharmaceutical Business in various senior marketing positions. After 20 years in several executive positions with Astra, Chris Thomas joins Dendrite to become Vice President of the following global accounts: Astra/Zeneca, Novartis, and Roche. As Dendrite's Vice President of Global Accounts, Simon Wicks will oversee Dendrite global relationships with Glaxo Wellcome, SmithKline Beecham and Pharmacia &Upjohn. Wicks' professional history includes business development positions with Glaxo Pharmaceuticals UK Ltd and Wyeth Laboratories Ltd. Gareth D. Thomas comes to Dendrite from his position as Pharmaceutical Business Manager at Integrated Sales Systems UK Ltd, where he was responsible for creating new business throughout Europe. Previous to his employment with ISS ISS See Institutional Shareholder Services (ISS). , Thomas worked at IMS Health ST in the roles of General Manager of Direct Marketing and Marketing Director of IMS Global The IMS Global Learning Consortium (usually known as IMS) is a non-profit standards organization concerned with establishing interoperability for learning systems and learning content and the enterprise integration of these capabilities. Services. He also sat on IMS's United Kingdom Board. In his role as Executive Director European Client Service, Bruno Chermette will implement an organizational and operational structure to optimize service delivery and maximize Dendrite's use of resources. Chermette has operated at General Manager level in the US, France and Spain as well as at a regional level. He has considerable experience in business re-engineering and has a broad knowledge of the pharmaceutical and healthcare industries. As Director of Sales in Canada, Robert Davis will continue to build upon his previous successes in highly competitive, key markets with global leaders in the pharmaceutical industry. In his most recent position at IMS Health ST, Davis served as Director of Business Development, developing new business as well as growing and maintaining the Canadian client base. Steve Turner joins Dendrite as Director of Technical Operations/Client Services for Canada after more than nine years with Walsh and then IMS Health ST, most recently as Walsh Director of Technology/Client Services in Canada. &uot;The addition of Rob Davis This article is about British musician Rob Davis. For the politician from Toronto, Ontario, Canada, see Rob Davis (Ontario politician). For the American Football player see Rob Davis (football player). For other uses, see Rob Davis (disambiguation). and Steve Turner to our team in Canada is indicative of Dendrite's vision to increase our presence in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. , as well as in other international locations,&uot; Bailye continued. &uot;Furthermore, Chris Thomas, Simon Wicks, Bruno Chermette and Gareth Thomas Gareth Thomas might refer to:
ABOUT DENDRITE As a leading global provider of highly-specialized, integrated product and service offerings for the Pharmaceutical and Consumer Package Goods (CPG CPG central pattern generators. ) industries, Dendrite supports corporate strategies for a sustained competitive advantage. Thousands of sales representatives and their managers from over 150 companies and 57 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. Focusing strongly on outcomes, Dendrite combines its modular software See modular programming. products with specifically tailored coaching and support services support services Psychology Non-health care-related ancillary services–eg, transportation, financial aid, support groups, homemaker services, respite services, and other services . With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception in 1986. Headquartered in Morristown, New Jersey Morristown is a town in Morris County, New Jersey, United States. As of the United States 2000 Census, the town population was 18,544. Its estimated population in 2004 was 18,842. It is the county seat of Morris CountyGR6. , Dendrite employs over 1200 people around the world. For more information, visit the Company's Web site at http://www.drte.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the scope of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, assumptions, estimates and projections about our company and the pharmaceutical and consumer packaged goods Noun 1. packaged goods - groceries that are packaged for sale foodstuff, grocery - (usually plural) consumer goods sold by a grocer plural, plural form - the form of a word that is used to denote more than one industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include the following: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs fixed costs, n.pl the costs that do not change to meet fluctuations in enrollment or in use of services (e.g., salaries, rent, business license fees, and depreciation). may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) we are exposed to risks associated with the Year 2000 (for example, (a) demand for our software products and services may decline before and after the Year 2000, (b) our Year 2000 remediation efforts may be unsuccessful and (c) we may incur material expenses in connection with any claim relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc Year 2000 compliance of our own products or the products of third parties); (ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and quarterly reports on Form 10-Q Form 10-Q See 10-Q. filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion